BACKGROUND: Sustained antibody levels are a hallmark of immunity against many pathogens, and induction of long-term durable antibody titers is an essential feature of effective vaccines. Heterologous prime-boost approaches with vectors are optimal strategies to improve a broad and prolonged immunogenicity of malaria vaccines. RESULTS: In this study, we demonstrate that the heterologous prime-boost regimen Ad35-CS/BCG-CS induces stronger immune responses by enhancing type 1 cellular producing-cells with high levels of CSp-specific IFN-γ and cytophilic IgG2a antibodies as compared to a homologous BCG-CS and a heterologous BCG-CS/CSp prime-boost regimen. Moreover, the heterologous prime-boost regimen elicits the highest level of LLPC-mediated immune responses. CONCLUSION: The increased IFN-γ-producing cell responses induced by the combination of Ad35-CS/BCG-CS and sustained type 1 antibody profile together with high levels of LLPCs may be essential for the development of long-term protective immunity against liver-stage parasites.
BACKGROUND: Sustained antibody levels are a hallmark of immunity against many pathogens, and induction of long-term durable antibody titers is an essential feature of effective vaccines. Heterologous prime-boost approaches with vectors are optimal strategies to improve a broad and prolonged immunogenicity of malaria vaccines. RESULTS: In this study, we demonstrate that the heterologous prime-boost regimen Ad35-CS/BCG-CS induces stronger immune responses by enhancing type 1 cellular producing-cells with high levels of CSp-specific IFN-γ and cytophilic IgG2a antibodies as compared to a homologous BCG-CS and a heterologous BCG-CS/CSp prime-boost regimen. Moreover, the heterologous prime-boost regimen elicits the highest level of LLPC-mediated immune responses. CONCLUSION: The increased IFN-γ-producing cell responses induced by the combination of Ad35-CS/BCG-CS and sustained type 1 antibody profile together with high levels of LLPCs may be essential for the development of long-term protective immunity against liver-stage parasites.
Authors: A V Bagaev; A V Pichugin; E S Lebedeva; A A Lysenko; M M Shmarov; D Yu Logunov; B S Naroditsky; R I Ataullakhanov; R M Khaitov; A L Gintsburg Journal: Acta Naturae Date: 2014-10 Impact factor: 1.845
Authors: Ekaterina A Koroleva; Natalie V Kobets; Dmitrii N Shcherbinin; Naylia A Zigangirova; Maxim M Shmarov; Amir I Tukhvatulin; Denis Y Logunov; Boris S Naroditsky; Alexander L Gintsburg Journal: Biomed Res Int Date: 2017-03-26 Impact factor: 3.411
Authors: Jessica Molina-Franky; Laura Cuy-Chaparro; Anny Camargo; César Reyes; Marcela Gómez; David Ricardo Salamanca; Manuel Alfonso Patarroyo; Manuel Elkin Patarroyo Journal: Malar J Date: 2020-02-03 Impact factor: 2.979
Authors: Amy R Noe; Diego Espinosa; Xiangming Li; Jordana G A Coelho-Dos-Reis; Ryota Funakoshi; Steve Giardina; Hongfan Jin; Diane M Retallack; Ryan Haverstock; Jeffrey R Allen; Thomas S Vedvick; Christopher B Fox; Steven G Reed; Ramses Ayala; Brian Roberts; Scott B Winram; John Sacci; Moriya Tsuji; Fidel Zavala; Gabriel M Gutierrez Journal: PLoS One Date: 2014-09-23 Impact factor: 3.240